Request Sample Inquiry
Heart Failure Drugs Market

Heart Failure Drugs Market

Heart Failure Drugs Market - Global Industry Assessment & Forecast

img
Healthcare
Number Of Pages # Pages:

250

Base Year:

2023

Date

Dec - 2024

Format:

PDF XLS PPT

Report Code:

VMR-3922

Segments Covered
  • By Drug Types By Drug Types Beta-Blockers, ACE Inhibitors, Angiotensin-Receptor Neprilysin Inhibitors, Angiotensin Receptor Blockers, Diuretic
  • By End User By End User Hospitals, Specialty Center, Others
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Snapshot
Base YearBase Year: 2023
Forecast YearsForecast Years: 2024 - 2032
Historical YearsHistorical Years: 2018 - 2022
Revenue 2023Revenue 2023: USD 8.6 Billion
Revenue 2032Revenue 2032: USD 21.4 Billion
Revenue CAGRRevenue CAGR (2024 - 2032): 12.1%
Fastest Growing Region Fastest Growing Region (2024 - 2032) Europe
Largest Region Largest Region (2023): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Heart Failure Drugs Market - Segment Analysis
    1. Overview
    2. Global Heart Failure Drugs Market, 2016 - 2028 (USD Million)
    3. Global Heart Failure Drugs Market - by Drug Types
      1. By Beta-Blockers
      2. By ACE Inhibitors
      3. By Angiotensin-Receptor Neprilysin Inhibitors
      4. By Angiotensin Receptor Blockers
      5. By Diuretic
    4. Global Heart Failure Drugs Market - by End User
      1. By Hospitals
      2. By Specialty Center
      3. By Others
    5. Global Heart Failure Drugs Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    6. Market comparative analysis
  4. North America Heart Failure Drugs Market - Segment Analysis
    1. Overview
    2. North America Heart Failure Drugs Market, 2016 - 2028 (USD Million)
    3. North America Heart Failure Drugs Market, by Drug Types
      1. By Beta-Blockers
      2. By ACE Inhibitors
      3. By Angiotensin-Receptor Neprilysin Inhibitors
      4. By Angiotensin Receptor Blockers
      5. By Diuretic
    4. North America Heart Failure Drugs Market, by End User
      1. By Hospitals
      2. By Specialty Center
      3. By Others
    5. North America Heart Failure Drugs Market, by Country
      1. U.S.
        1. U.S. Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. U.S. Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      2. Canada
        1. Canada Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Canada Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      3. Mexico
        1. Mexico Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Mexico Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
  5. Europe Heart Failure Drugs Market - Segment Analysis
    1. Overview
    2. Europe Heart Failure Drugs Market, 2016 - 2028 (USD Million)
    3. Europe Heart Failure Drugs Market, by Drug Types
      1. By Beta-Blockers
      2. By ACE Inhibitors
      3. By Angiotensin-Receptor Neprilysin Inhibitors
      4. By Angiotensin Receptor Blockers
      5. By Diuretic
    4. Europe Heart Failure Drugs Market, by End User
      1. By Hospitals
      2. By Specialty Center
      3. By Others
    5. Europe Heart Failure Drugs Market, by Country
      1. Germany
        1. Germany Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Germany Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      2. UK
        1. UK Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. UK Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      3. France
        1. France Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. France Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      4. Spain
        1. Spain Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Spain Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      5. Italy
        1. Italy Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Italy Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      6. BENELUX
        1. BENELUX Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. BENELUX Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      7. Rest of Europe
        1. Rest Of Europe Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Rest Of Europe Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
  6. Asia Pacific Heart Failure Drugs Market - Segment Analysis
    1. Overview
    2. Asia Pacific Heart Failure Drugs Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Heart Failure Drugs Market, by Drug Types
      1. By Beta-Blockers
      2. By ACE Inhibitors
      3. By Angiotensin-Receptor Neprilysin Inhibitors
      4. By Angiotensin Receptor Blockers
      5. By Diuretic
    4. Asia Pacific Heart Failure Drugs Market, by End User
      1. By Hospitals
      2. By Specialty Center
      3. By Others
    5. Asia Pacific Heart Failure Drugs Market, by Country
      1. China
        1. China Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. China Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      2. Japan
        1. Japan Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Japan Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      3. India
        1. India Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. India Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      4. South Korea
        1. South Korea Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. South Korea Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      5. South East Asia
        1. South East Asia Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. South East Asia Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Rest of Asia Pacific Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
  7. Latin America Heart Failure Drugs Market - Segment Analysis
    1. Overview
    2. Latin America Heart Failure Drugs Market, 2016 - 2028 (USD Million)
    3. Latin America Heart Failure Drugs Market, by Drug Types
      1. By Beta-Blockers
      2. By ACE Inhibitors
      3. By Angiotensin-Receptor Neprilysin Inhibitors
      4. By Angiotensin Receptor Blockers
      5. By Diuretic
    4. Latin America Heart Failure Drugs Market, by End User
      1. By Hospitals
      2. By Specialty Center
      3. By Others
    5. Latin America Heart Failure Drugs Market, by Country
      1. Brazil
        1. Brazil Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Brazil Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      2. Argentina
        1. Argentina Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Argentina Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      3. Rest of Latin America
        1. Rest of Latin America Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Rest of Latin America Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
  8. Middle East & Africa Heart Failure Drugs Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Heart Failure Drugs Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Heart Failure Drugs Market, by Drug Types
      1. By Beta-Blockers
      2. By ACE Inhibitors
      3. By Angiotensin-Receptor Neprilysin Inhibitors
      4. By Angiotensin Receptor Blockers
      5. By Diuretic
    4. Middle East & Africa Heart Failure Drugs Market, by End User
      1. By Hospitals
      2. By Specialty Center
      3. By Others
    5. Middle East & Africa Heart Failure Drugs Market, by Country
      1. GCC Countries
        1. GCC Countries Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. GCC Countries Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      2. South Africa
        1. South Africa Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. South Africa Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Heart Failure Drugs Market, By Drug Types
          1. By Beta-Blockers
          2. By ACE Inhibitors
          3. By Angiotensin-Receptor Neprilysin Inhibitors
          4. By Angiotensin Receptor Blockers
          5. By Diuretic
        2. Rest of Middle East & Africa Heart Failure Drugs Market, By End User
          1. By Hospitals
          2. By Specialty Center
          3. By Others
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Amgen
    2. Astrazeneca
    3. Bayer AG
    4. Novartis AG
    5. Gilead
    6. Pfizer Inc
    7. Teva Pharmaceuticals
    8. Cardior Pharmaceuticals GmbH
    9. GlaxoSmithKline
    10. Bristol-Myers Squibb Company
    11. Eli Lilly and Company
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
FAQ
Frequently Asked Question

  • The global Heart Failure Drugs valued at USD 8.6 Billion in 2023 and is expected to reach USD 21.4 Billion in 2032 growing at a CAGR of 12.1%.

  • The prominent players in the market are Amgen, Astrazeneca, Bayer AG, Novartis AG, Gilead, Pfizer Inc, Teva Pharmaceuticals, Cardior Pharmaceuticals GmbH, GlaxoSmithKline, Bristol-Myers Squibb Company, Eli Lilly and Company.

  • The market is project to grow at a CAGR of 12.1% between 2024 and 2032.

  • The driving factors of the Heart Failure Drugs include

  • North America was the leading regional segment of the Heart Failure Drugs in 2023.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy